دورية أكاديمية
أعرض في EDS

Atypical Rearrangements in APL-Like Acute Myeloid Leukemias: Molecular Characterization and Prognosis.

التفاصيل البيبلوغرافية
العنوان: Atypical Rearrangements in APL-Like Acute Myeloid Leukemias: Molecular Characterization and Prognosis.
المؤلفون: Guarnera L; Department of Biomedicine and Prevention, University of Tor Vergata, Rome, Italy., Ottone T; Department of Biomedicine and Prevention, University of Tor Vergata, Rome, Italy.; Santa Lucia Foundation, Istituto di Ricovero e Cura a Carattere Scientifico (I.R.C.C.S.) Neuro-Oncohematology, Rome, Italy., Fabiani E; Department of Biomedicine and Prevention, University of Tor Vergata, Rome, Italy.; Department of Biomedicine and Prevention, UniCamillus-Saint Camillus International University of Health Sciences, Rome, Italy., Divona M; Department of Biomedicine and Prevention, University of Tor Vergata, Rome, Italy., Savi A; Department of Biomedicine and Prevention, University of Tor Vergata, Rome, Italy., Travaglini S; Department of Biomedicine and Prevention, University of Tor Vergata, Rome, Italy., Falconi G; Department of Biomedicine and Prevention, University of Tor Vergata, Rome, Italy., Panetta P; Department of Biomedicine and Prevention, University of Tor Vergata, Rome, Italy., Rapanotti MC; Department of Biomedicine and Prevention, University of Tor Vergata, Rome, Italy.; Department of Experimental Medicine, Tor Vergata University of Rome, Rome, Italy., Voso MT; Department of Biomedicine and Prevention, University of Tor Vergata, Rome, Italy.; Santa Lucia Foundation, Istituto di Ricovero e Cura a Carattere Scientifico (I.R.C.C.S.) Neuro-Oncohematology, Rome, Italy.
المصدر: Frontiers in oncology [Front Oncol] 2022 Apr 12; Vol. 12, pp. 871590. Date of Electronic Publication: 2022 Apr 12 (Print Publication: 2022).
نوع المنشور: Journal Article; Review
اللغة: English
بيانات الدورية: Publisher: Frontiers Research Foundation] Country of Publication: Switzerland NLM ID: 101568867 Publication Model: eCollection Cited Medium: Print ISSN: 2234-943X (Print) Linking ISSN: 2234943X NLM ISO Abbreviation: Front Oncol Subsets: PubMed not MEDLINE
أسماء مطبوعة: Original Publication: [Lausanne : Frontiers Research Foundation]
مستخلص: Acute promyelocytic leukemia (APL) accounts for 10-15% of newly diagnosed acute myeloid leukemias (AML) and is typically caused by the fusion of promyelocytic leukemia with retinoic acid receptor α ( RARA ) gene. The prognosis is excellent, thanks to the all-trans retinoic acid (ATRA) and arsenic trioxide (ATO) combination therapy. A small percentage of APLs (around 2%) is caused by atypical transcripts, most of which involve RARA or other members of retinoic acid receptors ( RARB or RARG ). The diagnosis of these forms is difficult, and clinical management is still a challenge for the physician due to variable response rates to ATRA and ATO. Herein we review variant APL cases reported in literature, including genetic landscape, incidence of coagulopathy and differentiation syndrome, frequent causes of morbidity and mortality in these patients, sensitivity to ATRA, ATO, and chemotherapy, and outcome. We also focus on non-RAR rearrangements, complex rearrangements (involving more than two chromosomes), and NPM1-mutated AML, an entity that can, in some cases, morphologically mimic APL.
Competing Interests: The authors declare that the review was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.
(Copyright © 2022 Guarnera, Ottone, Fabiani, Divona, Savi, Travaglini, Falconi, Panetta, Rapanotti and Voso.)
References: Stem Cell Investig. 2019 Nov 26;6:37. (PMID: 31853453)
Blood. 1996 Feb 1;87(3):882-6. (PMID: 8562957)
Cancers (Basel). 2019 Nov 04;11(11):. (PMID: 31690038)
PLoS One. 2013;8(2):e57312. (PMID: 23468968)
Leukemia. 2005 Mar;19(3):470-2. (PMID: 15674421)
Leuk Res. 2019 Feb;77:14-16. (PMID: 30612054)
Leuk Lymphoma. 2019 Nov;60(11):2841-2843. (PMID: 31038019)
Leukemia. 2017 Apr;31(4):798-807. (PMID: 28111462)
Am J Hematol. 2020 Jul;95(7):E184-E186. (PMID: 32242976)
Int J Hematol. 2009 Jan;89(1):86-90. (PMID: 19052694)
Cold Spring Harb Perspect Biol. 2010 May;2(5):a000661. (PMID: 20452955)
Best Pract Res Clin Haematol. 2003 Sep;16(3):349-55. (PMID: 12935955)
Eur J Haematol. 2009 Nov;83(5):499-501. (PMID: 19624718)
Br J Haematol. 2021 Oct;195(2):e123-e128. (PMID: 34254314)
Blood. 1990 Dec 1;76(11):2418. (PMID: 2257311)
Mol Carcinog. 2021 Feb;60(2):. (PMID: 33428799)
Blood. 2008 Apr 1;111(7):3395-402. (PMID: 18195095)
Leukemia. 2017 Mar;31(3):747-751. (PMID: 27872498)
Circulation. 2011 Mar 15;123(10):e370-2. (PMID: 21403118)
Onco Targets Ther. 2020 Oct 15;13:10559-10566. (PMID: 33116634)
N Engl J Med. 2013 Jul 11;369(2):111-21. (PMID: 23841729)
Blood. 2019 Apr 11;133(15):1630-1643. (PMID: 30803991)
Int J Lab Hematol. 2021 Apr;43(2):218-226. (PMID: 33099879)
Blood Cells Mol Dis. 2018 Mar;69:71-73. (PMID: 29030091)
Blood. 2021 Dec 23;138(25):2696-2701. (PMID: 34343258)
Cancer Cell. 2017 Nov 13;32(5):552-560. (PMID: 29136503)
Blood. 2011 Jan 6;117(1):242-5. (PMID: 20935257)
Biomark Res. 2021 May 6;9(1):33. (PMID: 33957999)
Acta Med Scand. 1957 Nov 29;159(3):189-94. (PMID: 13508085)
J Leukoc Biol. 2019 Sep;106(3):717-723. (PMID: 31022319)
Nucl Recept Signal. 2009 May 12;7:e006. (PMID: 19471585)
Am J Hematol. 2020 Feb;95(2):E48-E51. (PMID: 31769058)
Cancers (Basel). 2020 May 21;12(5):. (PMID: 32455804)
Chemotherapy. 2019;64(5-6):238-247. (PMID: 32521534)
Nat Cell Biol. 2008 Feb;10(2):160-9. (PMID: 18193033)
Cancer Genet. 2015 Apr;208(4):162-3. (PMID: 25790901)
Blood. 2000 Aug 15;96(4):1297-308. (PMID: 10942371)
Oncogene. 1999 Jan 28;18(4):1113-8. (PMID: 10023688)
J Clin Oncol. 2021 May 10;39(14):1584-1594. (PMID: 33449813)
Genes Chromosomes Cancer. 2019 Jan;58(1):60-65. (PMID: 30421475)
Blood. 2018 Apr 19;131(16):1870-1873. (PMID: 29487068)
Blood. 2020 Aug 20;136(8):1011. (PMID: 32818249)
Blood. 2009 Jan 22;113(4):775-83. (PMID: 18945964)
Cancer Res. 2018 Aug 15;78(16):4452-4458. (PMID: 29921692)
Leukemia. 2001 Sep;15(9):1359-68. (PMID: 11516096)
Blood. 2018 Feb 22;131(8):935-939. (PMID: 29237593)
Int J Hematol. 2007 Oct;86(3):246-9. (PMID: 17988991)
Leuk Lymphoma. 2019 Jul;60(7):1831-1834. (PMID: 30632861)
Blood Adv. 2019 Oct 22;3(20):3157-3169. (PMID: 31648321)
Cancer Cell. 2019 Feb 11;35(2):177-190.e8. (PMID: 30686770)
Cancer Med. 2021 Jun;10(12):3839-3847. (PMID: 34042280)
Br J Haematol. 2021 Apr;193(1):129-132. (PMID: 32808672)
Leuk Res. 2018 Nov;74:51-54. (PMID: 30292835)
Leukemia. 2018 Oct;32(10):2285-2287. (PMID: 29568099)
Blood. 2004 Nov 15;104(10):3058-63. (PMID: 15217837)
Leukemia. 2018 Aug;32(8):1713-1726. (PMID: 29728695)
Am J Hematol. 2019 Oct;94(10):1091-1097. (PMID: 31292998)
J Clin Invest. 2020 May 1;130(5):2712-2726. (PMID: 32027624)
Blood. 1988 Aug;72(2):567-72. (PMID: 3165295)
Br J Haematol. 2015 Mar;168(6):904-8. (PMID: 25284716)
Rinsho Ketsueki. 2020;61(2):103-109. (PMID: 32147608)
Leuk Lymphoma. 2020 Dec;61(12):3018-3020. (PMID: 32657180)
Oncogene. 1999 Jan 21;18(3):633-41. (PMID: 9989813)
Pediatr Blood Cancer. 2012 Nov;59(5):959-60. (PMID: 22573339)
Leuk Lymphoma. 2015;56(9):2731-4. (PMID: 25629986)
Cold Spring Harb Mol Case Stud. 2015 Oct;1(1):a000307. (PMID: 27148563)
Cancers (Basel). 2019 Oct 18;11(10):. (PMID: 31635329)
Endocrinology. 2004 Dec;145(12):5452-8. (PMID: 15331577)
Leukemia. 1999 Dec;13(12):1901-28. (PMID: 10602411)
J Natl Compr Canc Netw. 2015 Jan;13(1):19-22. (PMID: 25583766)
Leukemia. 2006 Feb;20(2):376-9. (PMID: 16341036)
Onco Targets Ther. 2019 Aug 02;12:6157-6163. (PMID: 31447564)
Cancer Genet. 2012 Jun;205(6):327-31. (PMID: 22749039)
Cancers (Basel). 2020 Apr 14;12(4):. (PMID: 32295268)
Eur J Haematol. 2011 May;86(5):442-6. (PMID: 21447089)
Blood Rev. 2018 May;32(3):167-183. (PMID: 29157973)
Oncol Lett. 2018 Nov;16(5):6121-6125. (PMID: 30344754)
Haematologica. 2008 Sep;93(9):1414-6. (PMID: 18603554)
Blood. 2013 Feb 21;121(8):1432-5. (PMID: 23287866)
Oncol Lett. 2016 Dec;12(6):4717-4719. (PMID: 28101221)
Genes Chromosomes Cancer. 1996 Jan;15(1):26-33. (PMID: 8824722)
Cancer Genet. 2021 Nov;258-259:57-60. (PMID: 34534739)
Med Oncol. 2013 Mar;30(1):409. (PMID: 23292868)
Haematologica. 2011 Oct;96(10):1565-6. (PMID: 21750086)
Blood Cancer J. 2021 Oct 16;11(10):167. (PMID: 34657125)
Leukemia. 2017 Sep;31(9):1992-1995. (PMID: 28555082)
Oncoscience. 2014 Dec 27;2(1):50-8. (PMID: 25815362)
Hematol Rep. 2019 Sep 18;11(3):7971. (PMID: 31579135)
Int J Hematol. 2015 Dec;102(6):713-8. (PMID: 26342691)
Haematologica. 2020 Jul;105(7):e376-e378. (PMID: 32354871)
Blood. 2015 May 28;125(22):3455-65. (PMID: 25795919)
Blood. 2010 Nov 18;116(20):4274-83. (PMID: 20807888)
Blood. 2017 May 11;129(19):2705-2709. (PMID: 28314734)
Br J Cancer. 2019 May;120(11):1023-1025. (PMID: 30996344)
Mol Cell Biol. 2001 Mar;21(5):1672-81. (PMID: 11238904)
Eur J Haematol. 2008 May;80(5):444-7. (PMID: 18221386)
Blood. 1997 May 1;89(9):3345-53. (PMID: 9129041)
Leukemia. 1994 Aug;8(8):1350-3. (PMID: 8057672)
Br J Haematol. 2019 Oct;187(2):157-162. (PMID: 31410848)
Leukemia. 2019 Jun;33(6):1387-1399. (PMID: 30575821)
Epigenomics. 2019 May;11(7):835-855. (PMID: 31150281)
Blood. 2017 Jan 26;129(4):424-447. (PMID: 27895058)
Blood. 2015 May 28;125(22):3447-54. (PMID: 25800051)
Am J Hematol. 2018 Aug;93(4):504-510. (PMID: 29274134)
Blood. 2012 Aug 23;120(8):1570-80; quiz 1752. (PMID: 22715121)
Haematologica. 2019 May;104(5):e195-e199. (PMID: 30237272)
Haematologica. 2012 Mar;97(3):379-87. (PMID: 22058212)
Leuk Res. 2010 Feb;34(2):e55-7. (PMID: 19477513)
Blood. 2007 Dec 1;110(12):4073-6. (PMID: 17712046)
Nat Rev Cancer. 2010 Nov;10(11):775-83. (PMID: 20966922)
Leukemia. 2013 Jul;27(7):1606-10. (PMID: 23271512)
Blood Adv. 2018 Jun 12;2(11):1295-1299. (PMID: 29891591)
Int J Hematol. 2011 Oct;94(4):395-398. (PMID: 21927800)
Leuk Lymphoma. 2018 Mar;59(3):763-765. (PMID: 28760054)
Cancer Sci. 2016 Aug;107(8):1165-8. (PMID: 27193600)
Cancer Discov. 2021 Dec 1;11(12):3198-3213. (PMID: 34301789)
Am J Med. 1978 Oct;65(4):673-7. (PMID: 360835)
Front Pediatr. 2017 Feb 09;5:4. (PMID: 28232907)
Case Rep Hematol. 2015;2015:343854. (PMID: 25692052)
Front Oncol. 2016 Feb 03;6:21. (PMID: 26870698)
Leuk Lymphoma. 2018 Sep;59(9):2246-2249. (PMID: 29350080)
Blood. 2014 Aug 7;124(6):936-45. (PMID: 24782508)
Medicine (Baltimore). 2020 Oct 23;99(43):e22923. (PMID: 33120845)
Leukemia. 2016 Dec;30(12):2430. (PMID: 27713533)
Arch Pathol Lab Med. 2015 Oct;139(10):1308-13. (PMID: 26414475)
Blood. 2016 Sep 15;128(11):1525-8. (PMID: 27402972)
Hum Mol Genet. 1999 Sep;8(9):1741-9. (PMID: 10441338)
Ann Hematol. 2014 Nov;93(11):1931-3. (PMID: 24728721)
Exp Ther Med. 2019 Feb;17(2):1360-1366. (PMID: 30680014)
Blood. 1973 Apr;41(4):489-96. (PMID: 4510926)
Leukemia. 2000 Apr;14(4):722-6. (PMID: 10764161)
J Exp Med. 2013 Dec 16;210(13):2793-802. (PMID: 24344243)
Front Oncol. 2011 Oct 25;1:35. (PMID: 22655241)
Hematol J. 2004;5 Suppl 3:S133-7. (PMID: 15190295)
EBioMedicine. 2017 Jul;21:65-78. (PMID: 28673861)
Proc Natl Acad Sci U S A. 2000 Aug 29;97(18):10173-8. (PMID: 10954752)
Genes Dev. 2009 Sep 1;23(17):2076-87. (PMID: 19723763)
J Clin Pathol. 1963 Jul;16:319-24. (PMID: 14044032)
Front Oncol. 2021 Jun 24;11:688203. (PMID: 34249738)
فهرسة مساهمة: Keywords: APL-like acute myeloid leukemia; atypical rearrangements; complex rearrangements; genetic landscape; variant acute promyelocytic leukemia
تواريخ الأحداث: Date Created: 20220502 Latest Revision: 20220716
رمز التحديث: 20221213
مُعرف محوري في PubMed: PMC9039303
DOI: 10.3389/fonc.2022.871590
PMID: 35494081
قاعدة البيانات: MEDLINE
الوصف
تدمد:2234-943X
DOI:10.3389/fonc.2022.871590